FDA calls on firms to be ‘recall ready’ in final guidance
Regulatory NewsJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesComplianceMedical DevicesNorth AmericaOTCPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyRegulatory NewsJoanne S. EglovitchBiologics/ biosimilars/ vaccinesComplianceMedical DevicesNorth AmericaOTCPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy